Image Source: Keerthishivanand, CC BY-SA 4.0, via Wikimedia Commons
Apollo Hospitals Enterprise Limited (AHEL) today announced that its Board of Directors approved two significant matters during a meeting held on September 12, 2025. The board meeting commenced at 4:00 p.m. and concluded at 6:50 p.m..
The Board approved the execution of definitive share purchase agreements for the acquisition of 41,650,368 equity shares, aggregating to a 30.58% equity stake, in its subsidiary, Apollo Health and Lifestyle Limited (AHLL).
These shares were jointly held by the International Finance Corporation, Washington (IFC) and IFC EAF Apollo Investment Company (IFC EAF). The total purchase consideration for this acquisition amounted to Rs 12,540.68 million.
The shares were acquired at a price of Rs 301.09 per share. The deal will be completed once approval is secured from the Competition Commission of India.
Following the completion of this acquisition, AHLL will become a 99.42% subsidiary of AHEL, with the remaining 0.58% held under an ESOP pool.
The consideration for this acquisition is cash. AHLL, incorporated on November 10, 2000, is engaged in providing comprehensive healthcare services, including the operation of speciality hospitals, clinics, diagnostic centres, sugar clinics, dental clinics, and dialysis centres.
The turnover of AHLL for the financial year ended March 31, 2025, was Rs 15,535 million on a consolidated basis. The company’s turnover for the financial year 2023-24 was Rs 13,653 million, and for 2022-23 it was Rs 12,311 million. The acquisition does not fall within the ambit of a related party transaction.
In a separate approval, the Board sanctioned the setting up of a Comprehensive Oncology facility at Gurugram. This new facility will include a Single Gantry Proton Proteus One System.
The total investment designated for this project is Rs 5,730 million. The mode of financing for this investment will be through internal accruals. This Gurugram facility is planned as a 100-bed Comprehensive Oncology Centre.
It represents Apollo’s third Proton Therapy installation in India, adding to its existing centres in Chennai and Hyderabad.
The Chennai Proton Centre, the first in South Asia and the Middle East, has treated over 2,500 patients from 147 countries and currently treats more than 500 patients per annum.
The proposed Gurugram Proton Centre is designed to enable the treatment of an additional 350 patients per annum.
Apollo Hospitals compliance:
This disclosure was signed by S.M. Krishnan, Senior Vice President – Finance and Company Secretary, for Apollo Hospitals Enterprise Limited.
Disclaimer: The information provided is for educational purposes only and does not constitute financial advice. We are not registered financial advisors. Please conduct your own research and consult a qualified advisor before making investment decisions. Any investment decisions you make based on this information are solely at your own risk.
